Journal of Digestive Cancer Reports

Korean Society of Gastrointestinal Cancer Research (대한소화기암연구학회)
권호 표지

Effect of Helicobacter pylori Eradication on the Prevention of Gastric Cancer in the General Population with or without Precancerous Lesions: A Meta-analysis

일반 인구 집단에서 전암성 병변 유무에 따른 헬리코박터 제균 치료의 위암 예방 효과 연구: 메타분석

  • Kang, Soo Jin (Department of Internal Medicine, Seoul National University Bundang Hospital) ;
  • Shin, Cheol Min (Department of Internal Medicine, Seoul National University Bundang Hospital) ;
  • Kang, Seung Joo (Department of Internal Medicine, Seoul National University Hospital Healthcare System Gangnam Center)
  • 강수진 (분당서울대학교병원 내과) ;
  • 신철민 (분당서울대학교병원 내과) ;
  • 강승주 (서울대학교병원 강남센터 내과)
  • Received : 2020.10.31
  • Accepted : 2020.11.18
  • Published : 2020.12.31

⟨ Previous Next ⟩

Abstract

We performed a comprehensive meta-analysis on whether Helicobacter pylori (H. pylori) eradication can prevent gastric cancer in individuals with precancerous lesions (chronic atrophic gastritis, intestinal metaplasia, and dysplasia). The studies evaluating the effect of H. pylori eradication on gastric cancer were searched from PubMed, KoreaMed, EMBASE, and Cochrane Library. Subgroup analyses by precancerous lesions, regions and follow-up time were performed. Six randomized clinical trials were included. In the overall population, H. pylori eradication significantly decreased the risk of gastric cancer (risk ratio [RR]=0.56; 95% confidence interval [CI]: 0.41-0.77, p<0.01). Eradication therapy significantly reduced the risk of gastric cancer in Asian and group who followed up more than 10 years (RR=0.51; 95% CI: 0.35-0.73, p<0.01; I2=0%, p=0.46). However, subgroup analysis according to the precancerous lesions did not show any significant results (p>0.05). In the general population especially in Asian population, H. pylori eradication can reduce the risk of gastric cancer. The effect of the eradication treatment is remarkable upon the long-term follow-up. In contrast, there is insufficient evidence whether the eradication should be recommended for the individuals with precancerous lesions.

배경 및 목적: Helicobacter pylori (H. pylori) 제균 치료는 위암 발병률을 줄이는 것으로 알려져 있다. 그러나 만성 위축성 위염, 장상피화생 및 이형성증이 있는 일반 집단에서도 위암의 발생 위험을 예방할 수 있는지에 대해서는 여전히 논란의 여지가 있다. 우리는 포괄적인 메타분석을 통해 이에 대한 연구를 수행해 보고자 한다. 방법: 2019년 12월까지 H. pylori 제균 치료가 위암에 미치는 영향을 평가한 논문들을 PubMed, KoreaMed, EMBASE 및 Cochrane Library에서 검색하였다. 전암성 병변(만성 위축성 위염/장상피화생/이형성증), 지역(아시아/비아시아) 및 추적관찰기간에 따라 하위 집단 분석을 수행하였다. 모든 데이터는 Review Manager 5.3으로 분석하였다. 결과: 본 연구에서는 총 6편의 전향적 무작위 연구가 최종 분석에 포함되었다. 전체 집단에서 H. pylori 제균 치료는 위암 발생 위험을 유의하게 감소시켰다(위험비[RR]=0.56; 95% 신뢰구간[CI]: 0.41-0.77, p<0.01). 또한, 하위 집단 분석을 보면, H. pylori 제균 치료는 아시아 지역과 10년 이상의 추적관찰을 시행한 집단에서 위암 발생 위험을 현저하게 감소시키는 것을 보여주었다(RR=0.54, 95% CI: 0.39-0.75, p<0.01 및 RR=0.51; 95% CI: 0.35-0.73, p<0.01). 그러나, 전암성 병변 유무에 따른 하위 집단 분석에서는 유의한 결과가 도출되지 않았다(전암성 병변이 있는 군, RR=0.86, 95% CI: 0.47-1.59, p=0.63; 전암성 병변이 없는 군, RR=0.42, 95% CI: 0.02-7.69, p=0.56). 결론: H. pylori 제균 치료는 일반 집단, 특히 아시아 지역에서 위암 발생 위험을 낮춘다. 제균 치료의 위암 예방 효과는 10년 이상 장기간 추적관찰 하였을 때 유의하다. 한편, 전암성 병변이 있는 일반 집단에서 위암 예방을 위해 H. pylori 제균 치료를 시행하는 것은 아직 근거가 명확하지 않아 권고하기 어렵다. 따라서 앞으로 이에 대한 더 많은 연구가 필요하다.

Keywords

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. A Cancer Journal for Clinicians 2018;68(6):394-424. https://doi.org/10.3322/caac.21492
  2. The International Agency for Research on Cancer, Schistosomes, Liver Flukes and Helicobacter pylori. IARC monographs on the evaluation of carcinogenic risks to humans, No. 61. p1-241, Lyon, 1994.
  3. Correa P. A human model of gastric carcinogenesis. Cancer Research 1988;48(13):3554-3560.
  4. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. The New England Journal of Medicine 1991;325(16):1127-1131. https://doi.org/10.1056/NEJM199110173251603
  5. Choi IJ, Kook MC, Kim YI, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. The New England Journal of Medicine 2018;378(12):1085-1095. https://doi.org/10.1056/nejmoa1708423
  6. Lee YC, Chiang TH, Chou CK, et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology 2016;150(5):1113-1124.e5. https://doi.org/10.1053/j.gastro.2016.01.028
  7. Kim SG, Jung H-K, Lee HL, et al. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 Revised Edition. KJG 2013;62(1):3-26.
  8. Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015;64(9):1353. https://doi.org/10.1136/gutjnl-2015-309252
  9. El-Serag HB, Kao JY, Kanwal F, et al. Houston consensus conference on testing for Helicobacter pylori infection in the United States. Clinical Gastroenterology and Hepatology 2018;16(7):992-1002.e6. https://doi.org/10.1016/j.cgh.2018.03.013
  10. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the maastricht V/Florence consensus report. Gut 2017;66(1):6-30. https://doi.org/10.1136/gutjnl-2016-312288
  11. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. The American Journal of Gastroenterology 2017;112(2):212-239. https://doi.org/10.1038/ajg.2016.563
  12. Bae SE, Choi KD, Choe J, et al. The effect of eradication of Helicobacter pylori on gastric cancer prevention in healthy asymptomatic populations. Helicobacter 2018;23(2):e12464. https://doi.org/10.1111/hel.12464
  13. Choi IJ, Kim CG, Lee JY, et al. Family history of gastric cancer and Helicobacter pylori treatment. The New England Journal of Medicine 2020;382(5):427-436. https://doi.org/10.1056/nejmoa1909666
  14. Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ 2014;348:g3174. https://doi.org/10.1136/bmj.g3174
  15. Ford AC, Yuan Y, Forman D, Hunt R, Moayyedi P. Helicobacter pylori eradication for the prevention of gastric neoplasia. the cochrane database of systematic reviews. The Cochrane Library 2020;7(7):CD005583.
  16. Ford AC, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut 2020;69:2113-2121. https://doi.org/10.1136/gutjnl-2020-320839
  17. Kim N, Park RY, Cho SI, et al. Helicobacter pylori infection and development of gastric cancer in Korea: long-term followup. Journal of Clinical Gastroenterology 2008;42(5):448-454. https://doi.org/10.1097/MCG.0b013e318046eac3
  18. Shichijo S, Hirata Y, Niikura R, et al. Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication. Gastrointestinal Endoscopy 2016;84(4):618-624. https://doi.org/10.1016/j.gie.2016.03.791
  19. Chen H-N, Wang Z, Li X, Zhou Z-G. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer 2016;19(1):166-175. https://doi.org/10.1007/s10120-015-0462-7
  20. Massarrat S, Haj-Sheykholeslami A, Mohamadkhani A, et al. Precancerous conditions after H. pylori eradication: a randomized double blind study in first degree relatives of gastric cancer patients. Archives of Iranian Medicine 2012;15(11):664-669.
  21. Hwang YJ, Kim N, Lee HS, et al. Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication-a prospective study for up to 10 years. Alimentary Pharmacology & Therapeutics 2018;47(3):380-390. https://doi.org/10.1111/apt.14424
  22. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097
  23. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (Clinical Research ed) 2011;343:d5928. https://doi.org/10.1136/bmj.d5928
  24. Correa P, Fontham ET, Bravo JC, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. Journal of the National Cancer Institute 2000;92(23):1881-1888. https://doi.org/10.1093/jnci/92.23.1881
  25. Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291(2):187-194. https://doi.org/10.1001/jama.291.2.187
  26. Saito D. H. pylori infection and gastric cancer: Japanese intervention trial. Nihon Rinsho Japanese Journal of Clinical Medicine 2005;63 Suppl 11:35-40.
  27. Wong BC, Zhang L, Ma JL, et al. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut 2012;61(6):812-818. https://doi.org/10.1136/gutjnl-2011-300154
  28. Leung WK, Lin SR, Ching JY, et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 2004;53(9):1244-1249. https://doi.org/10.1136/gut.2003.034629
  29. Zhou L, Lin S, Ding S, et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. Chinese Medical Journal 2014;127(8):1454-1458. https://doi.org/10.3760/cma.j.issn.0366-6999.20132494
  30. You WC, Brown LM, Zhang L, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. Journal of the National Cancer Institute 2006;98(14):974-983. https://doi.org/10.1093/jnci/djj264
  31. Li WQ, Zhang JY, Ma JL, et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ (Clinical Research ed). 2019;366:l5016.
  32. Yoon H, Kim N, Lee HS, et al. Helicobacter pylori-negative gastric cancer in South Korea: incidence and clinicopathologic characteristics. Helicobacter 2011;16(5):382-388. https://doi.org/10.1111/j.1523-5378.2011.00859.x
  33. Kim N, Park YS, Cho S-I, et al. Prevalence and risk factors of atrophic gastritis and intestinal metaplasia in a Korean population without significant gastroduodenal disease. Helicobacter 2008;13(4):245-255. https://doi.org/10.1111/j.1523-5378.2008.00604.x
  34. Wang J, Xu L, Shi R, et al. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion 2011;83(4):253-260. https://doi.org/10.1159/000280318
  35. Rokkas T, Rokka A, Portincasa P. A systematic review and meta-analysis of the role of Helicobacter pylori eradication in preventing gastric cancer. Annals of Gastroenterology 2017;30(4):414-423.
  36. Li W-Q, Ma J-L, Zhang L, et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. JNCI: Journal of the National Cancer Institute 2014;106(7).
  37. Mera R, Fontham ET, Bravo LE, et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut 2005;54(11):1536-1540. https://doi.org/10.1136/gut.2005.072009
  38. Yanaoka K, Oka M, Ohata H, et al. Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels. International Journal of Cancer 2009;125(11):2697-2703. https://doi.org/10.1002/ijc.24591
  39. de Vries AC, van Grieken NCT, Looman CWN, et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology 2008;134(4):945-952. https://doi.org/10.1053/j.gastro.2008.01.071
  40. Leung WK, Wong IOL, Cheung KS, et al. Effects of Helicobacter pylori treatment on incidence of gastric cancer in older individuals. Gastroenterology 2018;155(1):67-75. https://doi.org/10.1053/j.gastro.2018.03.028